Genome editing

Genome editing Agency Consulting firm Experts Specialists Consultancy

Access the gene editing technology market

The Alcimed team has been exploring the technologies within the gene and genome editing field for more than 25 years, and supports its clients in their innovative projects, in understanding the current trends and markets for gene editing technologies, as well as in accessing the market.

    Tell us about your uncharted territory

    You have a project and want to discuss it with our explorers, write us!

    One of our explorers will contact you shortly.

    They trust us


    The challenges related to genome editing

    The development of genome editing therapy is a strongly growing field with many ongoing pre-clinical and clinical studies. Genome editing has the potential to address diseases with a large unmet medical need. Still, researchers, pharmaceutical companies, and biotech companies face several technical, ethical, as well as business-related challenges, and notably:

      Tell us about your uncharted territory

      You have a project and want to discuss it with our explorers, write us!

      One of our explorers will contact you shortly.

      How we support you in your project related to genome editing

      For more than 25 years, the Alcimed team has supported its clients on many issues related to gene therapy, and human genome editing technologies in gene therapy in particular. We have carried out many projects for our healthcare clients in fields such as oncology, ophthalmology, and veterinary medicine. Genome editing is also investigated as a promising technology for our agri-business clients.

      We have conducted projects in gene editing for European institutions and research centers, pharmaceutical companies, seeds companies, biotechs or patient associations.

      The diversity of our clients, the topics we cover, the geographic areas and the application areas we explore, and the types of projects we develop, give us a comprehensive and in-depth insight into issues related to genome editing.

      Our projects cover innovative technology within the field of genome editing, understanding current and future impact on companies’ business, the exploration of markets, the development of portfolio strategies, the search for partners, and many more!

      Examples of recent projects carried out for our clients in genome editing

      • Construction of a portfolio strategy in gene therapy

        One of our clients, a major player in gene therapy, wanted to understand how to develop its portfolio strategy by engaging in new therapeutic areas.

        To this end, Alcimed carried out 7 opportunity evaluations for different diseases by identifying their potential (disease severity, impact on the healthcare system, opportunity for gene therapy, patient population, etc.) and the associated risk (current treatments, risks for gene therapy linked to the care structure already in place, feasibility of a clinical trial, etc.).

        With the business cases built, the new therapeutic areas considered could be compared and prioritized, the synergies evaluated, in order to orient our client’s developments in a portfolio logic.

      • Support of a healthcare player in analyzing the field of genome editing and identifying key emerging technologies and start-ups in the field

        We supported one of our healthcare industry clients in identifying and evaluating the most innovative technologies within the field of gene editing.

        Through a global state-of-the-art, we confirmed the understanding of the current trends in the field of gene editing and the classification of the different technology types by interviewing key opinion leaders. We also identified key emerging start-ups, deciphered their technology and development stage, in order to recommend to our client a partner for further development.

        The output of our project for our client? A complete overview of current and future outlooks in the gene editing field, relevant companies and key contacts within the gene editing field, as well as key business opportunities.

      • Supporting an industry player in prioritizing relevant targets for the development of new drugs based on human genome editing technologies in ophthalmology

        We supported one of our clients in identifying the most innovative targets to develop a new gene therapy in the field of ophthalmology, using CRISPR genome editing technology.

        More than 30 gene candidates inherited in ocular disorders were identified and screened based on scientific, clinical and market criteria: epidemiology, unmet clinical needs of the disease, competition, current level of proof, existence of animal models… A clear prioritization appeared, and business cases were built to really engage our client in a new gene therapy development.

      • Support of an animal health company in its understanding of genome editing and genomic testing technologies

        One of our clients, a major player in animal heath, wanted to understand the current and future impacts of genome editing on its diagnostics business.

        Hence, we supported them in analyzing the current gene editing and genomic testing technologies for dairy and beef cattle worldwide. The main trends and regulatory evolutions were analyzed, and main players and their positioning were identified. We then organized a strategic workshop, to assess the coming threats or opportunities, and agree on the required actions to be taken by our client.

      • Landscaping of gene editing and delivery technologies for a biotech player

        Alcimed supported a biotechnology in understanding the current technological landscape of gene editing and transgene delivery technologies.

        To support them, our team performed a global analysis of tools for optimizing gene therapy by conducting a thorough technological and IP assessment in this field. The analyzed technologies included gene editing optimization, AAV optimization, expression regulation technologies, non-viral vectors, transgene optimization, and other tools. We then assessed the importance of these technologies based on their individual maturity levels and their compatibility with our client’s key selection criteria.

        Through this study, our client was able to gain an in-depth understanding of the state of the art of gene editing tools and a high priority list of technologies to pursue to develop their business portfolio.

      • Identification of academic and industrial players using gene engineering to produce botulinum toxin

        Alcimed supported an industrial player in understanding Asian players that specialize in gene engineering-based botulinum toxin production.

        With a focus on several Asian countries, our team identified and characterized the key academic and industrial players using genetic engineering to produce botulinum toxin. We then interacted directly with key stakeholders involved in this research domain and performed an in-depth desk research to gain a comprehensive understanding of the landscape for our client.

        Through this project, we helped our client have an overview of current research in this field, as well as an understanding of the most relevant players in their target geography. Our client could finally identify the most relevant business opportunities and potential partnerships.

      You have a project?

        Tell us about your uncharted territory

        You have a project and want to discuss it with our explorers, write us!

        One of our explorers will contact you shortly.

        To go further